Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTIF: Oral Immunotherapy for Cashew or Shrimp Allergies
NCT03504774Phase 2Terminated
- Start
- Jul 2019
- Primary completion
- Jan 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of shrimp oral immunotherapy in Cashew Allergy, crustacean shellfish allergy. Started Jul 2019; status: terminated.
02
Drugs
shrimp oral immunotherapy
03
Conditions
Cashew Allergycrustacean shellfish allergy
Beyond the preview
Go deeper on NCT03504774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504774.